Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy

Hung-Chang Liu, Shih-Kai Hung, Charn-Jer Huang, Chung-Chu Chen, Ming-Jen Chen, Chun-Chao Chang, Cheng-Jeng Tai, Chi-Yuan Tzen, Li-Hua Lu, Yu-Jen Chen, Hung-Chang Liu, Shih-Kai Hung, Charn-Jer Huang, Chung-Chu Chen, Ming-Jen Chen, Chun-Chao Chang, Cheng-Jeng Tai, Chi-Yuan Tzen, Li-Hua Lu, Yu-Jen Chen

Abstract

Aim: To compare the efficacy and toxicity of a three-step combination therapy with post-operative radiation alone for locally advanced esophageal cancer.

Methods: Patients with T3-4 and N0-1 esophageal carcinoma from a number of institutions were non-randomly, prospectively enrolled in the study. All patients underwent single-stage curative en bloc esophagectomy. The patients were then assigned into one of two treatment groups based on treatment consisting of either post-operative concurrent chemoradiotherapy (CCRT) with weekly cisplatin 30 mg/m2 followed by systemic adjuvant chemotherapy (four monthly cycles of cisplatin 20 mg/m2 and 5-fluorouracil 1 000 mg/m2 for five consecutive days), or, post-operative radiation alone. The radiotherapy dose was 55-60 Gy for all patients. Primary end-point of this study was to assess the per-protocol patients' improvement of overall survival benefit. Secondary end-point was designed to evaluate both the per-protocol and intent-to-treat patients' outcome of survival.

Results: A total of 60 patients (n = 30 per group) were enrolled in this study. The two groups were generally comparable for demographic characteristics and hematological and non-hematological toxicities. The CCRT with weekly cisplatin was well tolerated, with significantly better overall survival (30.9 mo vs 20.7 mo; 95% CI, 27.5-36.4 vs 15.2-26.1) and 3-year survival (70.0% vs 33.7%; P = 0.003). Low histological grade of tumor (P<0.001) was associated with favorable survival in these locally advanced patients.

Conclusion: For locally advanced esophageal cancer, the combination of esophagectomy, post-operative CCRT with weekly cisplatin and systemic adjuvant chemotherapy is well tolerated and effective. A large-scale, prospective randomized trial of this regimen is in progress.

Figures

Figure 1
Figure 1
Kaplan-Meier curves for overall survival as a function of treatment group. P value is 0.003 (A); Kaplan-Meier curves for overall survival as a function of squamous cell differentiation state (B).

Source: PubMed

3
購読する